Aberrant expression of NEK2 and its clinical significance in non‑small cell lung cancer

Zhong,Xinwen; Guan,Xiaojiao; Liu,Wenke; Zhang,Lin

doi:10.3892/ol.2014.2396

Aberrant expression of NEK2 and its clinical significance in non‑small cell lung cancer

Authors:
- Xinwen Zhong
- Xiaojiao Guan
- Wenke Liu
- Lin Zhang
View Affiliations

Affiliations: Department of Thoracic Surgery, The First Clinical College, China Medical University, Shenyang, Liaoning, P.R. China, Department of Pathology, The Second Clinical College, China Medical University, Shenyang, Liaoning, P.R. China
Published online on: July 30, 2014 https://doi.org/10.3892/ol.2014.2396
Pages: 1470-1476

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present study was to identify a potential biomarker that is more effective than those already available for the prognosis of non‑small cell lung cancer (NSCLC) patients. The expression of never in mitosis gene A (NIMA)‑related kinase 2 (NEK2), minichromosome maintenance complex component 7 (Mcm7) and Ki67 was evaluated in 270 NSCLC tissues using immunohistochemical and immunofluorescence techniques. Associations between protein expression and clinicopathological characters were assessed, and the impact on overall survival was analyzed. High levels of NEK2, Mcm7 and Ki67 expression were detected in 25.9, 35.2 and 24.4% of the NSCLC tissues. Overexpression of NEK2 was detected more frequently in cases with high T and N stages (P<0.0001 and P=0.011, respectively). Correlations were present between the expression of NEK2, Mcm7 and Ki67. Kaplan‑Meier curves indicated that the patients with overexpressed NEK2, Mcm7 and Ki67 had a poorer overall survival time compared to those with low expression for all stages (P<0.0001). In particular, the patients with NEK2 overexpression had a poorer prognosis. Multivariate Cox regression analysis showed that NEK2, Mcm7 and Ki67 are independent prognostic indicators for NSCLC. In conclusion, the data indicate that compared with Mcm7 and Ki67, NEK2 may be a more effective tumor proliferation marker of poor prognosis for NSCLC patients, and that NEK2 may represent a novel potential target for NSCLC therapeutic intervention.

View Figures

View References

1	Siegel R, Ward E, Brawley O and Jemal A: Cancer Statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011.
2	Herbst RS, Heymach JV and Lippman SM: Lung Cancer. N Engl J Med. 359:1367–1380. 2008.
3	Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M and Tanimoto M: Role of adjuvant chemotherapy in patients with resected non-small cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol. 22:3860–3867. 2004.
4	Wu W, Baxter JE, Wattam SL, et al: Alternative splicing controls nuclear translocation of the cell cycle-regulated NEK2 kinase. J Biol Chem. 282:26431–26440. 2007.
5	Sankaran S and Parvin JD: Centrosome functions in normal and tumor cells. J Cell Biochem. 99:1240–1250. 2006.
6	Tsunoda N, Kokuryo T, Oda K, et al: Nek2 as a novel molecular target for the treatment of breast carcinoma. Cancer Sci. 100:111–116. 2009.
7	Rees M, Stahl M, Klump B, Willers R, Gabbert HE and Sarbia M: The prognostic significance of proliferative activity, apoptosis and expression of DNA topoisomerase II alpha in multimodally-treated esophageal squamous cell carcinoma. Anticancer Res. 21:3637–3642. 2001.
8	Pugsley JM, Schmidt RA and Vesselle H: The KI-67index and survival in non-small cell lung cancer: a review and relevance to position emission tomography. Cancer J. 8:222–233. 2002.
9	Daidone MG and Silvestrini R: Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. J Natl Cancer Inst Monogr. 2001.27–35
10	Lara PC, Rey A, Santana C, Afonso JL, Diaz JM, Gonzalez GJ, et al: The role of Ki67 proliferation assessment in predicting local control in bladder cancer patients treated by radical radiation therapy.
11	Shepherd NA, Richman PI and England J: Ki67 derived proliferative activity in colorectal adenocarcinoma with prognostic correlations. J Pathol. 155:213–219. 1988.
12	Toyokawa G, Masuda K, Daigo Y, Cho HS, Yoshimatsu M, Takawa M, et al: Mini chromosome maintenance protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer. Mol Cancer. 10:652011.
13	Scholzen T and Gerdes J: The Ki67 protein: from the known and the unknown. J Cell Physiol. 182:311–322. 2000.
14	Lei M and Tye BK: Initiating DNA synthesis: from recruiting to activating the MCM complex. J Cell Sci. 114:1447–1454. 2001.
15	Zhong X, Li M, Nie B, et al: Overexpression of RACK1 and CD147 associated with poor prognosis in stage T1 pulmonarey adenocarcinoma. Ann Surg Oncol. 20:1044–1052. 2013.
16	Remmele W and Schicketanz KH: Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs subjective grading (IRS). Patho Res Pract. 189:862–866. 1993.
17	Ganem NJ, Godinho SA and Pellman D: A mechanism linking extra centrosomes to chromosomal instability. Nature. 460:278–282. 2009.
18	Niu Y, Liu T, Tse GM, et al: Increased expression of centrosomal alpha, gamma-tubulin in atypical ductal hyperplasia and carcinoma of the breast. Cancer Sci. 100:580–587. 2009.
19	Bahmanyar S, Kaplan DD, Deluca JG, et al: Beta-catenin is a Nek2 substrate involved in centrosome separation. Genes Dev. 22:91–105. 2008.
20	Hayward DG, Newbatt Y, Pickard L, et al: Identification by high throughput screening of viridian analogs as biochemical and cell based inhibitors of the cell cycle regulated NEK2 kinase. J Biomol Screen. 15:918–927. 2010.
21	Fry AM: The NEK2 protein kinase: a novel regulator of centrosome structure. Oncogene. 21:6184–6194. 2002.
22	Fletcher L, Cerniglia GJ, Nigg EA, Yend TJ and Muschel RJ: Inhibition of centrosome separation after DNA damage: a role for NEK2. Radiat Res. 162:128–135. 2004.
23	Hayward DG, Clarke RB, Faragher AJ, Pillai MR, Hagan IM and Fry AM: The centrosomal kinase NEK2 displays elevated levels of protein expression in human breast cancer. Cancer Res. 64:7370–7376. 2004.
24	Shuling W, Weidong L, Shuhua L, Yahong W, Ziyu L, Jing Z, Tieju L and Yun N: Abnormal expression of Nek2 and β-catenin in breast carcinoma: clinicopathological correlations. Histopathology. 59:631–642. 2011.
25	Gozuacik D, Chami M, Lagorce D, et al: Identification and functional characterization of a new member of the human Mcm protein family. Nucleic Acids Res. 2:570–579. 2003.
26	Labib K, Tercero JA and Diffley JF: Uninterrupted Mcm2–7 function required for DNA replication fork progression. Science. 288:1643–1647. 2000.
27	Crevel C, Ivetic A, Ohno K, et al: Nearest neighbor analysis of Mcm protein complexes in drosophila melanogaster. Nucl Acids Res. 29:4834–4842. 2001.
28	Lee JK and Hurwitz J: Possessive DNA helices activity of the mini chromosome maintenance protein 4, 6 and 7 complexes requires forked DNA structures. Proc Natl Acad Sci USA. 98:54–59. 2001.
29	Fujioka S, Shomori K, Nishihara K, Yagama K, Nosaka K, Araki K, Araki K, et al: Expression of minichromosome maintenance 7 (Mcm7) in small lung adenocarcinomas (pT1): prognostic implication. Lung Cancer. 65:223–229. 2009.
30	Marnerides A, Vassilakopoulos TP, Boltetsou E, et al: Immunohistochemical expression and prognostic significance of CCND3, Mcm2 and Mcm7 in Hodgkin lymphoma. Anticancer Res. 31:3585–3594. 2011.
31	Lobato S, Tafuri A, Fernandes PA, Caliari MV, et al: Mini chromosome maintenance 7 protein is a reliable biological marker for human cervical progressive decease. J Gyneco Oncol. 23:11–15. 2012.